-
Clinical trial of dry eye treatment drug reproxalap clinical 2b yields positive results
Time of Update: 2020-06-11
dry eye disease is a common inflammatory disease that affects about 20 million people in the United States The disease is characterized by inadequate moisture and lubrication on the front surface of
-
GlaxoSmithKline M72/AS01E candidate vaccine gets positive results in Phase 2b clinical trial
Time of Update: 2020-06-11
tuberculosis is one of the leading causes of infectious disease death worldwide It is estimated that one quarter of the world's population is infected with latent tuberculosis, in which case mycobact
-
Dermira gets positive results in clinical trial of new drug lebrikizumab2b phase 2b
Time of Update: 2020-06-10
today, Dermira (http:// announced that the company developed a new drug (http:// in the treatment of severe isotrophic dermatitis, which in the http:// of the 2b dose increment severity tria
-
Seltorexant (MIN-202) reaches primary and critical secondary endpoint in Phase 2b clinical trials for insomnia patients
Time of Update: 2020-06-09
today, Minerva company (http:// announced that the company's joint development with Janssen,""min-202" reached the primary and critical secondary endpoint sydd of the trial in the phase 2b clinic
-
Karyopharm's innovative therapy Xpovio (selinexor) Phase 2b clinical trial yields positive results
Time of Update: 2020-06-08
recently, Karyopharm Therapeutics company (http:// announced positive results from the of its innovative clinical (http:// for the treatment of recurrent/incurable multiple myeloma study was
-
Cirius's candidate drug MSDC-0602K showed positive results in stage 2b trial EMMINENCE for the treatment of NASH
Time of Update: 2020-06-07
recently, Cirius (http:// announced that its main drug (http:// MSDC-0602K, significantly improving patients' liver enzyme levels, blood sugar control, and insulin resistance in the phase 2b
-
Reducing the risk of vascular calcification Innovative therapies reach the clinical end of Phase 2b
Time of Update: 2020-06-01
In patients with chronic kidney disease, especially end-stage nephropathy, metabolic and hormonal abnormalities lead to inflammation, malnutrition, mineral metabolism abnormalities, anemia and other s
-
Uber anti-epileptic new drug padsevonil 2b clinical failure!
Time of Update: 2020-05-31
UCB recently released the results of the study of the new anti-epileptic drug padsevonil IIb (NCT03373383) The results showed that, during the 12-week maintenance period, padsevonil did not achieve a
-
Oral JAK inhibitor Filgotinib treatment UC 2b/3 clinical to the main endpoint
Time of Update: 2020-05-28
The compilation of S.Li days ago, Gilead and Galapagos jointly announced that the oral JAK inhibitor Filgotinib, jointly developed by the two companies, had achieved positive results in the 2b/3 clin
-
Characteristics of patients with missing tumors with CDKN2A/2B copy number
Time of Update: 2020-05-28
CDKN2A is located on chromosome 9, encodes a cell cycle hormone-dependent kinase inhibitor 2a, which is an anti-cancer gene At least three different splicing variants of the gene are reported, two o
-
Clinical approval of pegylated recombinant human interferon α 2B injection in Anke
Time of Update: 2020-04-03
On the evening of May 22, an kebio announced that the company's self-developed and characteristic pegylated recombinant human interferon α 2B injection was approved by the State Food and Drug Administ
-
Xiamen Tebao new drug pegylated interferon α - 2b injection is the first in China to be approved soon
Time of Update: 2020-04-03
According to the information on CFDA's website on November 5, Tonghua Dongbao (600867 SH), a joint-stock company of Xiamen Tebao, will enter the GMP field inspection this month Industry insiders predi
-
Xiamen Tebao a new drug pegylated interferon α - 2b injection officially declared for production
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), Tonghua Dongbao joint stock company Xiamen Tebao Bioengineering Co., Ltd has officially applied for the production of polyeth
-
PEGylation of recombinant human interferon α 2B injection will be approved in clinical
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on May 12, the status of pegylated recombinant human interferon α 2B injection (hereinafter referred to as "long-acting interf
-
Targeted energy metabolism Nash innovative therapy stage 2B positive clinical results
Time of Update: 2019-11-10
Recently, cirius therapeutics announced that its main candidate drug, msdc-0602k, has significantly improved the liver enzyme level, blood glucose control and insulin resistance of patients in the pha